0001564590-20-042855 Sample Contracts

Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

BioNTech SE • September 9th, 2020 • Biological products, (no disgnostic substances)

• Company
  BioNTech SE
• Filed
  September 9th, 2020
• Industry
  Biological products, (no disgnostic substances)

• The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval